Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Sell
48
AXIM Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
44.33%
Day range:
$0.0110 - $0.0127
52-week range:
$0.0026 - $0.0288
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
127.90x
P/B ratio:
--
Volume:
29.2K
Avg. volume:
327.6K
1-year change:
297.83%
Market cap:
$4M
Revenue:
$70.5K
EPS (TTM):
-$0.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AXIM
AXIM Biotechnologies, Inc.
|
-- | -- | -- | -- | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.62% | -58.59% | $467.62 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835.5M | $0.67 | 11.91% | 37.43% | $88.65 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AXIM
AXIM Biotechnologies, Inc.
|
$0.0119 | -- | $4M | -- | $0.00 | 0% | 127.90x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.03 | $31.21 | $3.7B | 14.17x | $0.00 | 0% | 3.54x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$314.40 | $467.62 | $41.7B | 139.29x | $0.00 | 0% | 11.30x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$59.87 | $88.65 | $11.5B | 22.43x | $0.00 | 0% | 3.79x |
|
IMNN
Imunon, Inc.
|
$3.25 | $21.50 | $6.9M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$5.60 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AXIM
AXIM Biotechnologies, Inc.
|
-224.48% | -1.951 | 226.27% | 0.00x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.236 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AXIM
AXIM Biotechnologies, Inc.
|
-- | -$268.7K | -- | -- | -11619.41% | -$133.1K |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
AXIM Biotechnologies, Inc. vs. Competitors
-
Which has Higher Returns AXIM or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -12985.96% compared to AXIM Biotechnologies, Inc.'s net margin of 25.76%. AXIM Biotechnologies, Inc.'s return on equity of -- beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies, Inc.90.02% -$0.00 -$2.9M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About AXIM or ACAD?
AXIM Biotechnologies, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 41.67%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than AXIM Biotechnologies, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than AXIM Biotechnologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies, Inc.0 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is AXIM or ACAD More Risky?
AXIM Biotechnologies, Inc. has a beta of -0.567, which suggesting that the stock is 156.736% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock AXIM or ACAD?
AXIM Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or ACAD?
AXIM Biotechnologies, Inc. quarterly revenues are $17.5K, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. AXIM Biotechnologies, Inc.'s net income of -$234.3K is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, AXIM Biotechnologies, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies, Inc. is 127.90x versus 3.54x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies, Inc.127.90x -- $17.5K -$234.3K ACADACADIA Pharmaceuticals, Inc.3.54x 14.17x $278.6M $71.8M
-
Which has Higher Returns AXIM or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -12985.96% compared to AXIM Biotechnologies, Inc.'s net margin of 16.99%. AXIM Biotechnologies, Inc.'s return on equity of -- beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies, Inc.90.02% -$0.00 -$2.9M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About AXIM or ALNY?
AXIM Biotechnologies, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $467.62 which suggests that it could grow by 48.74%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than AXIM Biotechnologies, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than AXIM Biotechnologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies, Inc.0 0 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is AXIM or ALNY More Risky?
AXIM Biotechnologies, Inc. has a beta of -0.567, which suggesting that the stock is 156.736% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock AXIM or ALNY?
AXIM Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or ALNY?
AXIM Biotechnologies, Inc. quarterly revenues are $17.5K, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. AXIM Biotechnologies, Inc.'s net income of -$234.3K is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, AXIM Biotechnologies, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 139.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies, Inc. is 127.90x versus 11.30x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies, Inc.127.90x -- $17.5K -$234.3K ALNYAlnylam Pharmaceuticals, Inc.11.30x 139.29x $1.1B $186.4M
-
Which has Higher Returns AXIM or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -12985.96% compared to AXIM Biotechnologies, Inc.'s net margin of -3.91%. AXIM Biotechnologies, Inc.'s return on equity of -- beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies, Inc.90.02% -$0.00 -$2.9M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About AXIM or BMRN?
AXIM Biotechnologies, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.65 which suggests that it could grow by 48.07%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than AXIM Biotechnologies, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than AXIM Biotechnologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies, Inc.0 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is AXIM or BMRN More Risky?
AXIM Biotechnologies, Inc. has a beta of -0.567, which suggesting that the stock is 156.736% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock AXIM or BMRN?
AXIM Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or BMRN?
AXIM Biotechnologies, Inc. quarterly revenues are $17.5K, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. AXIM Biotechnologies, Inc.'s net income of -$234.3K is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, AXIM Biotechnologies, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 22.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies, Inc. is 127.90x versus 3.79x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies, Inc.127.90x -- $17.5K -$234.3K BMRNBioMarin Pharmaceutical, Inc.3.79x 22.43x $786.8M -$30.7M
-
Which has Higher Returns AXIM or IMNN?
Imunon, Inc. has a net margin of -12985.96% compared to AXIM Biotechnologies, Inc.'s net margin of --. AXIM Biotechnologies, Inc.'s return on equity of -- beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies, Inc.90.02% -$0.00 -$2.9M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About AXIM or IMNN?
AXIM Biotechnologies, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 561.54%. Given that Imunon, Inc. has higher upside potential than AXIM Biotechnologies, Inc., analysts believe Imunon, Inc. is more attractive than AXIM Biotechnologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies, Inc.0 0 0 IMNNImunon, Inc.3 1 0 -
Is AXIM or IMNN More Risky?
AXIM Biotechnologies, Inc. has a beta of -0.567, which suggesting that the stock is 156.736% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.
-
Which is a Better Dividend Stock AXIM or IMNN?
AXIM Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or IMNN?
AXIM Biotechnologies, Inc. quarterly revenues are $17.5K, which are larger than Imunon, Inc. quarterly revenues of --. AXIM Biotechnologies, Inc.'s net income of -$234.3K is higher than Imunon, Inc.'s net income of -$3.4M. Notably, AXIM Biotechnologies, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies, Inc. is 127.90x versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies, Inc.127.90x -- $17.5K -$234.3K IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns AXIM or SVRA?
Savara, Inc. has a net margin of -12985.96% compared to AXIM Biotechnologies, Inc.'s net margin of --. AXIM Biotechnologies, Inc.'s return on equity of -- beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies, Inc.90.02% -$0.00 -$2.9M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About AXIM or SVRA?
AXIM Biotechnologies, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 93.08%. Given that Savara, Inc. has higher upside potential than AXIM Biotechnologies, Inc., analysts believe Savara, Inc. is more attractive than AXIM Biotechnologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies, Inc.0 0 0 SVRASavara, Inc.6 0 0 -
Is AXIM or SVRA More Risky?
AXIM Biotechnologies, Inc. has a beta of -0.567, which suggesting that the stock is 156.736% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock AXIM or SVRA?
AXIM Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or SVRA?
AXIM Biotechnologies, Inc. quarterly revenues are $17.5K, which are larger than Savara, Inc. quarterly revenues of --. AXIM Biotechnologies, Inc.'s net income of -$234.3K is higher than Savara, Inc.'s net income of -$29.6M. Notably, AXIM Biotechnologies, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies, Inc. is 127.90x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies, Inc.127.90x -- $17.5K -$234.3K SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
